Heim
Tíðindir
Umseting
Verkætlan
Torg
Hjálp
Limir
Innrita
Skráset
. .
•Vangamynd
ervintoth
•Allar umsetingar
▪▪Umbidnar umsetingar
•
Yndis umsetingar
•Listi av verkætlanum
•Inbox
▪Ókeypis mál samskifti
•English
•Türkçe
•Français
•Español
•Italiano
•Português brasileiro
•Deutsch
•Română
•عربي
•Русский
•Svenska
•Ελληνικά
•Български
•עברית
•Shqip
•Srpski
•Nederlands
•Dansk
•Português
•Polski
•汉语(简体)
•Lietuvių
•Norsk
•فارسی
•Suomi
•Hrvatski
•日本語
•Català
•Esperanto
•한국어
•Українська
▪▪Føroyskt
•नेपाली
•Kiswahili
Allar umsetingar
Leita
Umbidnar umsetingar - ervintoth
Leita
Uppruna mál
Ynskt mál
Úrslit 1 - 2 av okkurt um 2
1
384
Uppruna mál
ASSESSMENT OF SMALL BOWEL SAFETY OF LUMIRACOXIB 100 MG OD
Of 152 randomized subjects, 139 completed the study with valid VCEs. Compared with placebo, an increased number of subjects on naproxen plus omeprazole had small bowel mucosal breaks , with increased permeability and raised faecal calprotectin . .There was no increase in permeability. As assessed by three different measures, acute small bowel injury on lumiracoxib treatment is less frequent than with naproxen plus omeprazole and similar to placebo.
Fullfíggjaðar umsetingar
Uppskattning av lumiracoxibs 100 mg od tunntarmssäkerhet
1